• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·DLCL.BO
Share

Dr Lalchandani Labs Limited Stocks

₹ 7.15Last Updated 21.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 318968.76843

₹ 7.15
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dr. Lalchandani Labs Ltd. specializes in providing diagnostic and allied healthcare services. The company furnishes both individuals and medical practitioners with a wide array of diagnostic tests and services. These offerings are vital for fundamental health screening, patient diagnosis, and the proactive prevention, ongoing monitoring, and effective treatment of illnesses and other medical conditions. Arjan Lal Chandani founded this enterprise in 1986, and its primary operations are based in New Delhi, India.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 14:02

eBay shares rose following the announcement of a 9% workforce reduction. Should you buy these stocks?

22.10.2026 13:20

The Euro vs. the Barricades: What Affects Its Exchange Rate More Than the Crisis in France

22.10.2026 13:06

Another sell-off in tech stocks: Meta and Tesla failed to calm the market

22.10.2026 12:23

Nebius highlighted the difference from CoreWeave amid concerns about Neocloud's debt

22.10.2026 11:49

Meta is ramping up its investment in AI: increasing spending and preparing to issue a new class of shares

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026